Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination-Reference-Cited by-同舟云学术

Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination

Published:2017-09 Issue:5 Volume:16 Page:734-741
ISSN:1665-2681
Container-title:Annals of Hepatology
language:en
Short-container-title:Annals of Hepatology

Author:

Tamori Akihiro,Hai Hoang,Uchida-Kobayashi Sawako,Enomoto Masaru,Kozuka Ritsuzo,Motoyama Hiroyuki,Kawamura Etsushi,Hagihara Atsushi,Teranishi Yuga,Yoshida Kanako,Morikawa Hiroyasu,Murakami Yoshiki,Kawada Norifumi

Publisher

Elsevier BV

Subject

Hepatology,General Medicine

Reference25 articles.

1. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care;Pearlman;Lancet Infect Dis,2012

2. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders;Imai;J Viral Hepat,2010

3. Effect of aging on risk for hepatocel-lular carcinoma in chronic hepatitis C virus infection;Asahina;Hepa-tology,2010

4. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection;Hézode;N Engl J Med,2009

5. Simeprevir with peginterferon/ ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial;Hayashi;J Hepatol,2014

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of combined antiretroviral therapy (cART) in Hepatitis B and C associated hepatocellular carcinoma (HCC): a narrative review;Journal of Human Virology & Retrovirology;2023-12-29

2. Serum Mac-2-binding protein glycosylation isomer predicts esophagogastric varices in cirrhotic patients with chronic hepatitis C virus infection treated with IFN-free direct-acting antiviral agent: M2BPGi levels predict varices in SVR patients;Annals of Hepatology;2020-07

3. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals;World Journal of Gastroenterology;2020-06-07

4. Favorable outcome of retreatment by direct‐acting antivirals for hepatitis C patients with daclatasvir plus asunaprevir combination therapy failure;Hepatology Research;2019-12-19

5. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis;Journal of Hepatology;2019-09